Halozyme Therapeutics has expanded its collaboration with argenx, increasing exclusive access to its ENHANZE® drug delivery technology from six to eight targets. This expansion strengthens their partnership, allowing argenx to develop more immunology treatments with improved subcutaneous delivery, enhancing patient convenience and treatment experience. Halozyme will receive milestone payments and royalties from products using ENHANZE®, which facilitates rapid, large-volume drug delivery. The deal highlights the growing demand for patient-friendly therapies and the broad potential of ENHANZE® across various medical fields.
Halozyme's expanded collaboration with argenx is presented here with Pluang's Health-sector market data as of Oct 07, 2026 03:04 WIB. Of 100 priced Health-sector US stocks tradable on Pluang, 47 rose and 53 fell today. Notable movers include ADPT at USD 29.93 with a 1-day change of +5.57%, SANA at USD 2.75 down 4.69%, and MESO at USD 13.58 down 4.50%.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
